Accord BioPharma Celebrates 10,000 Patients Treated with CAMCEVI® for Advanced Prostate Cancer

Accord BioPharma Celebrates CAMCEVI® Milestone

Accord BioPharma, Inc., the U.S. division of Intas Pharmaceuticals, has announced a notable achievement: over 10,000 patients have accessed CAMCEVI® (leuprolide) 42 mg injectable emulsion, a significant treatment option in the fight against advanced prostate cancer. This milestone, recognized in early 2025, highlights the drug's vital role in enabling both patients and healthcare providers to combat this prevalent disease.

The drug, which received FDA approval in May 2021, was launched commercially in March 2022. CAMCEVI is the first ready-to-inject, sterile formulation of leuprolide mesylate for subcutaneous injection, provided in a prefilled syringe that requires no mixing. This aspect simplifies the process for healthcare professionals, making it easier to deliver effective treatment.

Chrys Kokino, the U.S. president of Accord, expressed pride in this accomplishment, emphasizing the company's ongoing commitment to making affordable therapies accessible to patients. "This CAMCEVI milestone illustrates our success in delivering on that promise while providing healthcare providers with an effective treatment option that is easy to administer," said Kokino.

The relevance of CAMCEVI in today's healthcare landscape is underscored by rising rates of advanced prostate cancer. The American Cancer Society identifies prostate cancer as the most frequently diagnosed cancer among American men, aside from skin cancers. Concerns regarding decreased screening rates and an aging population make treatments like CAMCEVI increasingly important.

Individuals affected by prostate cancer have shared positive experiences with CAMCEVI. Peter, a patient undergoing treatment for recurring advanced prostate cancer, praised the convenience of the medication's six-month injection schedule. He stated, "I just had my third injection. The every six months dosing is convenient for me." Peter has also taken initiative by starting a fitness group for men dealing with prostate cancer, further showcasing the sense of community among patients.

In an effort to ensure that all men impacted by prostate cancer receive the necessary resources, Accord BioPharma offers the AccordCares® program, which features a nurse-staffed helpline and copay assistance. To date, this initiative has supported over 2,300 patients, demonstrating their dedication to comprehensive patient care.

Sarah Locasto, a nurse educator and prostate cancer navigator, noted how the simplified preparation of CAMCEVI enhances workflow efficiency. "What appealed to me was the simplified preparation, knowing that it already came prefilled and that you don't have to mix it. I typically give about 40 injections in a day, so convenience is very important to me," she remarked.

Accord BioPharma is not only focused on treatment but also aims to increase awareness and support regarding prostate cancer. Through the PRO•STATE of Mind campaign, the company encourages education about the disease, advocating for early screening and community involvement. Their partnership with ZERO Prostate Cancer reinforces this mission by striving to create positive changes within affected communities.

For patients and their loved ones, learning more about CAMCEVI is vital. The treatment is indicated for adult patients with advanced prostate cancer, but it is also essential to consider the potential side effects associated with GnRH agonists. A full understanding of the drug allows patients to make informed decisions regarding their health.

To know more about CAMCEVI and its benefits, visit camcevi.com. This achievement by Accord BioPharma not only epitomizes their goal of increasing access to effective cancer therapies but also reflects their broader commitment to transforming lives through dedicated healthcare solutions.